Sign in
WithdrawnPhase 3

High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda

Key facts

Who runs it
Virginia Commonwealth University
Where
Rwanda1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 3
Started
Oct 2022
Ended
Dec 2023
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ascorbic Acid 500Mg/Ml Inj
  • Dextrose in Water
Record updated
18 October 2022
Why it stopped
Recent studies suggest an increase in mortality due to high-does Vitamin C

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adult patients between the ages of 18 and 80 who provide informed consent (or consent obtained by family member if patient is incapacitated) AND
  • Patients with a strong suspicion or confirmation of infection AND
  • Presence of organ dysfunction brought on by sepsis. This defined by an increase of two or more points in the qSOFA score

Who cannot take part

  • Known allergic reaction to ascorbic acid
  • History of renal stones
  • History of end-stage renal disease (ESRD) requiring dialysis
  • History of hemochromatosis
  • History of glucose-6-phosphatase dehydrogenase (G6PD) deficiency
  • Pregnant patients or those who may be pregnant

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This feasibility study serves to determine if it is possible to perform a powered randomized control trial of high-dose intravenous vitamin C (ascorbic acid) as an adjunctive medication in the management of sepsis and septic shock in Rwanda. Further data will be collected including Sequential Organ Failure Assessment (SOFA) score, Universal Vital Assessment (UVA) score, duration of vasopressors, mortality and other key indicators to possibly determine the impact of vitamin C on organ failure and clinical course. A total of 24 patients with a diagnosis of sepsis or septic shock will be recruited after obtaining informed consent at the University Teaching Hospital of Kigali (CHUK) and will be randomized in a 1:1 fashion to receive drug or placebo. Both treatment arms will receive standard treatment (intravenous fluids, antibiotics, vasopressors as needed, etc.) in addition to study drug or placebo.

Read full original descriptionShow less

During the course of the study, any difficulties encountered will be recorded and will inform process improvements for a full randomized control, if it is indeed considered possible to perform the definitive trial.

The 2 groups in the trial

  • Treatment armTreatment being tested

    The study drug is ascorbic acid is 200mg/kg/day divided over 4 doses per day and delivered in 50 ml of 5% dextrose in water intravenously over a total duration of 96 hours.

    Treatment: Ascorbic Acid 500Mg/Ml Inj

  • Placebo armPlacebo, for comparison

    The placebo is 50ml of 5% dextrose in water and will be administered 4 doses per day over a total duration of 96 hours

    Treatment: Dextrose in Water

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda: a Feasibility Trial
Record updated
18 October 2022